Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.016 | 0.1964 | 0.0151 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0317 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0317 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0317 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0196 | 0.3805 | 0.2407 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0317 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0317 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0317 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0158 | 0.1841 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0317 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0317 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0317 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0317 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0317 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0281 | 0.8159 | 0.8159 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0196 | 0.3805 | 0.3805 |
Giardia lamblia | Hypothetical protein | 0.0281 | 0.8159 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.0281 | 0.8159 | 0.8159 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0317 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0317 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0317 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0121 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0317 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0121 | 0 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0317 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0317 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0121 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0121 | 0 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0317 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0196 | 0.3805 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0281 | 0.8159 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0317 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0281 | 0.8159 | 0.8159 |
Brugia malayi | FAD binding domain containing protein | 0.0317 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0158 | 0.1841 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0317 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0317 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0121 | 0 | 0.5 |
Treponema pallidum | flavodoxin | 0.0121 | 0 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0196 | 0.3805 | 0.3805 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 500 uM | Inhibitory activity against human Nitric oxide synthase-I with 2 uM H4Bip for 30 min | ChEMBL. | 16033258 |
IC50 (binding) | > 500 uM | Inhibitory activity against human Nitric oxide synthase-II with 2 uM H4Bip for 30 min | ChEMBL. | 16033258 |
IC50 (binding) | > 500 uM | Inhibitory activity against human Nitric oxide synthase-III with 2 uM H4Bip for 30 min | ChEMBL. | 16033258 |
IC50 (binding) | > 500 uM | Inhibitory activity against human Nitric oxide synthase-I with 2 uM H4Bip for 30 min | ChEMBL. | 16033258 |
IC50 (binding) | > 500 uM | Inhibitory activity against human Nitric oxide synthase-II with 2 uM H4Bip for 30 min | ChEMBL. | 16033258 |
IC50 (binding) | > 500 uM | Inhibitory activity against human Nitric oxide synthase-III with 2 uM H4Bip for 30 min | ChEMBL. | 16033258 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.